Please login to the form below

Not currently logged in
Email:
Password:

Array Biopharma hires Dr Howard Holden as VP regulatory affairs

Will oversee attempts to bring to market pipeline of small molecule drugs to treat cancer and inflammatory diseases

Dr Howard Holden has joined Array Biopharma as VP of regulatory affairs and quality assurance.

Dr Holden will handle regulatory proceedings as the US biopharma aims to bring to market its pipeline of small molecule drugs to treat cancer and inflammatory diseases.

He has spent over 25 years in the pharma and biotech industry, including most recently 7 years at Nereus Pharmaceuticals as senior VP regulatory affairs and compliance.

Previously, Dr Holden was VP of regulatory affairs and compliance at Stressgen Biotechnologies and Ligand Pharmaceuticals; senior director at Parke-Davis/Warner-Lambert, director at Centocor and senior investigator at the US National Cancer Institute.

"Howard's lifetime of regulatory experience will help Array navigate the FDA approval path for our proprietary programmes," said Kyle Lefkoff, executive chair, Array BioPharma.

"He will make an immediate contribution as we move our pipeline into registration studies, and we're all excited to have Howard on the Array team."

27th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics